Repligen Corporation (RGEN)
|Net Income (ttm)||145.81M|
|Day's Range||147.20 - 153.39|
|52-Week Range||137.21 - 327.32|
|Price Target||244.67 (+63.2%)|
|Earnings Date||Apr 27, 2022|
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput... [Read more...]
In 2021, Repligen's revenue was $670.53 million, an increase of 83.08% compared to the previous year's $366.26 million. Earnings were $128.29 million, an increase of 114.08%.Financial Statements
According to 14 analysts, the average rating for RGEN stock is "Buy." The 12-month stock price forecast is 244.67, which is an increase of 63.16% from the latest price.
The declining pace of COVID-19 vaccination programs is likely to hurt Repligen's (RGEN) revenue growth rate in 2022. However, the strong core business is likely to offer a respite.
Repligen (RGEN) reports encouraging first-quarter results with both sales and earnings beating estimates. RGEN also reduced its financial guidance for 2022
A stronger-than-expected earnings report calls months of the stock's weakness into question.
Repligen (RGEN) delivered earnings and revenue surprises of 27.78% and 12.45%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
—Record revenue of $206.4 million for the quarter, and year-over-year growth of 45% as reported and 48% at constant currency
Management has executed its strategy well, but a potential risk is looming.
Webcast and Conference Call to Be Held Wednesday, April 27, 2022 at 8:30 a.m. EDT Webcast and Conference Call to Be Held Wednesday, April 27, 2022 at 8:30 a.m. EDT
WALTHAM, Mass., March 18, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtua...
BOSTON--(BUSINESS WIRE)--908 Devices has appointed Tony J. Hunt, President and CEO of Repligen Corporation to serve on its Board of Directors effective immediately.
Repligen's (RGEN) fourth-quarter earnings and revenues beat estimates. It expects to achieve revenue growth in the range of 19-24% in 2022.
Repligen (RGEN) delivered earnings and revenue surprises of 24.62% and 3.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
— Record revenue of $186.5 million for the quarter, and year-over-year growth of 72%
Let us take a look at four biotech or drug companies - RGEN, IRWD, EXEL and LGND - due to release their quarterly results on Feb 16.
AVIPure® affinity resins address the market need for high performance and caustic stability AVIPure® affinity resins address the market need for high performance and caustic stability
WALTHAM, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtual...
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Webcast and Conference Call to Be Held Thursday, February 17, 2022 at 8:30 a.m. EST Webcast and Conference Call to Be Held Thursday, February 17, 2022 at 8:30 a.m. EST
New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position VRTX, REGN, DVAX ...
These two companies offer under-the-radar ways to invest in the healthcare space.
Repligen (RGEN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ea...
WALTHAM, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtual...
Here we present three biotech companies, which are likely to perform well in 2022, backed by strong fundamentals.
Repligen (RGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Here is how Repligen (RGEN) and Roche Holding AG (RHHBY) have performed compared to their sector so far this year.